title: [Therapy of primary brain tumors with segidrin].
abstract: The results of segidrin administration to 46 patients with malignant and 6 patients with benign tumors of the brain are presented. Pronounced therapeutic effect for the whole group was 63.5% and 73%, if partial regression of neurologic symptoms in the entire brain and separate foci is considered. These indexes for patients with malignant tumors only were 61 and 71.7%, respectively. Since segidrin has virtually no significant untoward side-effects, it is considered a most safe medicine for managing brain tumors. It is recommended in cases of inoperable tumor and for post-operative adjuvant chemotherapy with a view to extending the patient's survival time and improving the quality of life.
authors.forename: V A
authors.initials: VA
authors.lastname: Filov
authors.forename: M L
authors.initials: ML
authors.lastname: Gershanovich
authors.forename: B A
authors.initials: BA
authors.lastname: Ivin
authors.forename: L A
authors.initials: LA
authors.lastname: Danova
authors.forename: F A
authors.initials: FA
authors.lastname: Gurchin
authors.forename: A G
authors.initials: AG
authors.lastname: Naryshkin
authors.forename: V I
authors.initials: VI
authors.lastname: Leshchinskiĭ
authors.forename: A G
authors.initials: AG
authors.lastname: Zemskaia
authors.forename: B M
authors.initials: BM
authors.lastname: Nikiforov
authors.forename: P V
authors.initials: PV
authors.lastname: Breĭvis
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy*; D002648:Child; D005260:Female; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D006834:Hydrazines; C029424:hydrazine